28 Citations (Scopus)

Abstract

Introduction: Brain metastases (BM) commonly occur in patients with lung adenocarcinoma and usually lead to a poor prognosis and quality of life despite of radiotherapy. Epidermal growth factor receptor ( EGFR) mutations have been widely demonstrated to be a predictive and prognostic factor for lung adenocarcinoma, however, its impact on BM from lung adenocarcinoma remains inconclusive. The present study aimed to elucidate the predictive role of EGFR mutations in BM treatment response and survival after BM in patients with lung adenocarcinoma. Material and methods: From January 2006 through February 2012, 180 of 505 lung adenocarcinoma patients developed BM during their disease course were reviewed for eligibility, and 139 patients, including 89 EGFR-mutant and 50 EGFR wild-type patients, were identified for analysis. Results: Of the patients eligible for evaluation of treatment response, up to 85% received radiotherapy and the remaining took EGFR tyrosine kinase inhibitors (TKIs) as the front modality for BM. EGFR-mutant patients, compared with EGFR wild-type patients, had significantly greater intracranial treatment response of BM (84% vs. 48%, P= 0.002), experienced higher therapeutic efficacy to radiotherapy (86% vs. 52%, P= 0.005), and had longer median survival after BM diagnosis (13.2 vs. 6.8 months, P

Original languageEnglish
Pages (from-to)455-461
Number of pages7
JournalLung Cancer
Volume81
Issue number3
DOIs
Publication statusPublished - Sep 2013

Fingerprint

Epidermal Growth Factor Receptor
Neoplasm Metastasis
Mutation
Survival
Brain
Radiotherapy
Therapeutics
Adenocarcinoma of lung
Protein-Tyrosine Kinases
Quality of Life

Keywords

  • Brain metastases
  • Epidermal growth factor receptor mutations
  • Lung adenocarcinoma
  • Radiotherapy
  • Survival after brain metastases
  • Treatment response

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

@article{0d1386d3f6e14eecb8a60f5b2f1f0ee1,
title = "Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients",
abstract = "Introduction: Brain metastases (BM) commonly occur in patients with lung adenocarcinoma and usually lead to a poor prognosis and quality of life despite of radiotherapy. Epidermal growth factor receptor ( EGFR) mutations have been widely demonstrated to be a predictive and prognostic factor for lung adenocarcinoma, however, its impact on BM from lung adenocarcinoma remains inconclusive. The present study aimed to elucidate the predictive role of EGFR mutations in BM treatment response and survival after BM in patients with lung adenocarcinoma. Material and methods: From January 2006 through February 2012, 180 of 505 lung adenocarcinoma patients developed BM during their disease course were reviewed for eligibility, and 139 patients, including 89 EGFR-mutant and 50 EGFR wild-type patients, were identified for analysis. Results: Of the patients eligible for evaluation of treatment response, up to 85{\%} received radiotherapy and the remaining took EGFR tyrosine kinase inhibitors (TKIs) as the front modality for BM. EGFR-mutant patients, compared with EGFR wild-type patients, had significantly greater intracranial treatment response of BM (84{\%} vs. 48{\%}, P= 0.002), experienced higher therapeutic efficacy to radiotherapy (86{\%} vs. 52{\%}, P= 0.005), and had longer median survival after BM diagnosis (13.2 vs. 6.8 months, P",
keywords = "Brain metastases, Epidermal growth factor receptor mutations, Lung adenocarcinoma, Radiotherapy, Survival after brain metastases, Treatment response",
author = "Hsiao, {Shih Hsin} and Lin, {Horng Chyuan} and Chou, {Yu Ting} and Lin, {Sey En} and Kuo, {Chia Chun} and Yu, {Ming Chih} and Chung, {Chi Li}",
year = "2013",
month = "9",
doi = "10.1016/j.lungcan.2013.06.004",
language = "English",
volume = "81",
pages = "455--461",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients

AU - Hsiao, Shih Hsin

AU - Lin, Horng Chyuan

AU - Chou, Yu Ting

AU - Lin, Sey En

AU - Kuo, Chia Chun

AU - Yu, Ming Chih

AU - Chung, Chi Li

PY - 2013/9

Y1 - 2013/9

N2 - Introduction: Brain metastases (BM) commonly occur in patients with lung adenocarcinoma and usually lead to a poor prognosis and quality of life despite of radiotherapy. Epidermal growth factor receptor ( EGFR) mutations have been widely demonstrated to be a predictive and prognostic factor for lung adenocarcinoma, however, its impact on BM from lung adenocarcinoma remains inconclusive. The present study aimed to elucidate the predictive role of EGFR mutations in BM treatment response and survival after BM in patients with lung adenocarcinoma. Material and methods: From January 2006 through February 2012, 180 of 505 lung adenocarcinoma patients developed BM during their disease course were reviewed for eligibility, and 139 patients, including 89 EGFR-mutant and 50 EGFR wild-type patients, were identified for analysis. Results: Of the patients eligible for evaluation of treatment response, up to 85% received radiotherapy and the remaining took EGFR tyrosine kinase inhibitors (TKIs) as the front modality for BM. EGFR-mutant patients, compared with EGFR wild-type patients, had significantly greater intracranial treatment response of BM (84% vs. 48%, P= 0.002), experienced higher therapeutic efficacy to radiotherapy (86% vs. 52%, P= 0.005), and had longer median survival after BM diagnosis (13.2 vs. 6.8 months, P

AB - Introduction: Brain metastases (BM) commonly occur in patients with lung adenocarcinoma and usually lead to a poor prognosis and quality of life despite of radiotherapy. Epidermal growth factor receptor ( EGFR) mutations have been widely demonstrated to be a predictive and prognostic factor for lung adenocarcinoma, however, its impact on BM from lung adenocarcinoma remains inconclusive. The present study aimed to elucidate the predictive role of EGFR mutations in BM treatment response and survival after BM in patients with lung adenocarcinoma. Material and methods: From January 2006 through February 2012, 180 of 505 lung adenocarcinoma patients developed BM during their disease course were reviewed for eligibility, and 139 patients, including 89 EGFR-mutant and 50 EGFR wild-type patients, were identified for analysis. Results: Of the patients eligible for evaluation of treatment response, up to 85% received radiotherapy and the remaining took EGFR tyrosine kinase inhibitors (TKIs) as the front modality for BM. EGFR-mutant patients, compared with EGFR wild-type patients, had significantly greater intracranial treatment response of BM (84% vs. 48%, P= 0.002), experienced higher therapeutic efficacy to radiotherapy (86% vs. 52%, P= 0.005), and had longer median survival after BM diagnosis (13.2 vs. 6.8 months, P

KW - Brain metastases

KW - Epidermal growth factor receptor mutations

KW - Lung adenocarcinoma

KW - Radiotherapy

KW - Survival after brain metastases

KW - Treatment response

UR - http://www.scopus.com/inward/record.url?scp=84881667804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881667804&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2013.06.004

DO - 10.1016/j.lungcan.2013.06.004

M3 - Article

C2 - 23871711

AN - SCOPUS:84881667804

VL - 81

SP - 455

EP - 461

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -